Neural Noise

Transcranial ultrasound stimulation for emotion and sleep self-regulation

3 min read

  • Transcranial ultrasound stimulation (TUS) can be leveraged to enhance self-regulation in emotion and sleep.1
  • TUS offers a non-invasive neuromodulation alternative to tDCS and tACS for self-regulation applications.1
  • Peer-reviewed work in Frontiers supports methods relevance for stimulation pipelines; implementation remains early.1 1

Weekly enrichment (2026-07-20)

  • The source is a Frontiers in Human Neuroscience Perspective article (2025) proposing transcranial ultrasound stimulation (TUS) as a non-invasive tool for enhancing emotion and sleep self-regulation in healthy individuals, combined with neurofeedback and cognitive training to prolong its neuroplastic effects.2
  • TUS uses focused ultrasound waves to reach both cortical and deep subcortical targets with high (submillimeter) spatial precision, distinguishing it from tDCS, tACS, and TMS, which are limited in depth penetration.2 3
  • A 2025 systematic review of human studies identified 11 tFUS emotion-regulation studies targeting the amygdala (n = 5), prefrontal cortex (n = 5), or subcallosal cingulate cortex (n = 1), with protocols spanning 250–650 kHz, duty cycles of 0.5–70%, and 1–25 sessions.3
  • Across the six of those studies reporting behavioral symptom outcomes, the pooled effect was moderate-to-large (Hedges’ g = 0.88, 95% CI [0.47, 1.29]), larger for depression measures (g = 1.31) than anxiety measures (g = 0.67), with no serious adverse events reported.3
  • A Molecular Psychiatry (2025) study delivered MRI-guided tFUS to the left amygdala: a double-blind, sham-controlled, within-subject target-engagement arm (N = 29 patients with mood/anxiety/trauma-related disorders plus 23 healthy controls) showed active vs. sham stimulation reduced left amygdala BOLD signal.4
  • Its unblinded treatment arm used 3 weeks of daily repetitive tFUS (15 sessions), was well-tolerated with no serious adverse events, and yielded a significant primary-outcome reduction (Mood and Anxiety Symptom Questionnaire General Distress; p = 0.001, Cohen’s d = 0.77) plus secondary effects of Cohen’s d 0.43–1.50.4
  • A representative inhibitory amygdala LIFU protocol delivers 650 kHz sonication at a 10 Hz pulse repetition frequency and 5% duty cycle, 720 mW/cm² spatial-peak temporal-average intensity, in 30-s on / 30-s off blocks for 10 cycles over 10 minutes, at mechanical index 1.7 (below the FDA limit of 1.9) with an estimated thermal dose of ~0.18 CEM43°C, far below the 240 CEM43°C tissue-necrosis threshold.5
  • On the sleep side, a wearable ultrasound patch (NEUSLeeP, ~103.4 g) integrates six electrophysiology channels (4 EEG, 1 EOG, 1 EMG) with a concentric-ring ultrasound transducer array targeting the subthalamic nucleus to enhance REM sleep during overnight use.6

Footnotes

  1. https://news.google.com/rss/articles/CBMinAFBVV95cUxPR1BGcy00Mnl2cUFPdGJvSTRUUG5USGNiOExmTFI1NGlYUlAtbFZVNFBXZU1YM3BPd25DQlFMTmtPbGpyNThBXzdvc0xsNjZ3RUhKX3Z0Q2JjZlhyeFV3ZUFITkJJV0xDSGJJNVM1YVlJeTRQWjFBY1lsUk5LSEVxMnFPTmlWSGJNdXo3eExxVHJ4Ny00TXExT0RFNDY?oc=5 ↩ ↩2 ↩3 ↩4

  2. https://doi.org/10.3389/fnhum.2025.1594106 ↩ ↩2

  3. https://www.medrxiv.org/content/10.1101/2025.09.03.25334438v2 ↩ ↩2 ↩3

  4. https://doi.org/10.1038/s41380-025-03033-w ↩ ↩2

  5. https://www.frontiersin.org/journals/neuroimaging/articles/10.3389/fnimg.2025.1580623/full ↩

  6. https://doi.org/10.1101/2025.10.19.683337 ↩

Graph View